Heterocyclic ether substituted imidazoquinolines and pharmaceutical compositions for cytokine induction, anti-tumor activty and antiviral activity

摘要

The compounds of formula (I)-(IX) and (XLIV) or pharmaceutically acceptable salts are described wherein: X is -CHR3-, -CHR3-alkyl- or-CHR3-alkenyl-; R1 is -heteroaryl, -heterocyclyl, -R4-heteroaryl or -R4-heterocyclyl, and in formulas (V) and (VI) R1 can also be -(CH2)1-10-CºC-R10; R2 is -hydrogen, -alkyl, -alkenyl, -aryl, -heteroaryl, -heterocyclyl, -alkyl-Y-alkyl, -alkyl-Y-alkenyl, -alkyl-Y-aryl, or -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of -OH, -halogen, -N(R3)2, -CO-N(R3)2, -CO-C1-10alkyl, -CO-O-C1-10alkyl, - N3, -aryl, -heteroaryl, -heterocyclyl, -CO-aryl, and -CO-heteroaryl; R4 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; Each R3 is independently H or C1-10alkyl; Each Y is independently -O-or-S(O)0-2-; n is 0 to 4; and each R present is independently selected from the group consisting of C1-10alkyl, C1-10 alkoxy, hydroxy, halogen and trifluoromethyl; and R10 is heteroaryl and heterocyclyl; R7 is tert-butyl or benzyl; and Z is NH2 or NO2. The compounds can be used in the manufacture of a pharmaceutical composition for inducing cytokine biosynthesis, preferably the cytokine IFN-a, for treating viral disease and for treating neoplastic disease.